Vyome Holdings, Inc. reported revenue of approximately $320 thousand in FY2025 against sustained net losses exceeding $10 million. The strategic merger with ReShape Lifesciences in mid-2025 introduces potential synergies but also operational complexities amid ongoing clinical development delays. Core clinical assets VT-1953 and VB-1953 approach pivotal regulatory milestones with orphan drug designations enhancing exclusivity prospects. Liquidity remains constrained at roughly $5 million cash with a near 2x current ratio, necessitating prudent capital management including convertible note acquisitions via subsidiary LiveChain. Execution risks persist due to the company's limited commercialization history and clinical trial uncertainties, setting the stage for critical FDA interactions in H1 2026.